Abstract: Alzheimer's disease (AD) represents a devastating neurodegenerative disorder with profound societal and individual implications. Despite advancements in understanding its clinical trajectory, current diagnostic approaches often lag behind the onset of irreversible neural damage, highlighting the critical need for innovative strategies that enable early detection. This study integrates genomic profiling with neurobiological pathway mapping to elucidate early biomarkers and mechanistic insights that precede cognitive decline. By merging data-driven techniques with molecular and cellular neuroscience, the research aims to bridge the gap between genetic predisposition and phenotypic manifestation of the disease. Central to this work is a multidisciplinary framework that synergizes large-scale genomic datasets with neural imaging and molecular pathway analyses. Genetic loci implicated in AD—such as APOE, PSEN1, and PSEN2—are examined alongside transcriptional networks and epigenomic modifications to identify signature patterns associated with preclinical disease states. Concurrently, neurobiological mapping sheds light on disruptions in synaptic signaling, neuroinflammatory cascades, and metabolic deficits in brain regions vulnerable to AD pathology. The integration of these domains permits an unprecedented resolution of the interplay between genetic architecture and neurobiological dysregulation, uncovering potential avenues for therapeutic intervention. This work advances translational science by proposing actionable biomarkers and computational models for risk stratification in asymptomatic populations. The findings carry broader implications for personalized medicine, particularly in enhancing predictive accuracy and tailoring preventive strategies to an individual’s genomic and neurobiological profile. By situating early detection within a systems biology context, the study underscores the importance of interdisciplinary analyses to dismantle the complexity of Alzheimer’s disease and foster novel avenues for clinical innovation.
Keywords: Alzheimer's Disease, Early Detection, Genomic Profiling, Neurobiological Pathways, Biomarker Discovery, Multi-omics Integration, Precision Medicine, Transcriptomics, Neuroimaging, Gene Expression Analysis, Epigenetics, Systems Biology, Neural Network Mapping, Pathway Enrichment Analysis, Disease Risk Stratification.
|
DOI:
10.17148/IJARCCE.2023.121225
